Contemporary preoperative parameters predict cancer-free survival after radical prostatectomy: A tool to facilitate treatment decisions

Urologic Oncology: Seminars and Original Investigations

Volumn 21, Issue 3, 2003, Pages 213-218

  Nelson, Caleb P ^a   Dunn, Rodney L ^a   Wei, John T ^a   Rubin, Mark A ^a   Montie, James E ^a   Sanda, Martin G ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Pathology; Predictive models; Prostate cancer; Prostate specific antigen; Radical prostatectomy; Survival

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE; AGED; BLOOD LEVEL; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CONFERENCE PAPER; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RACE; STATISTICAL ANALYSIS; SURVIVAL TIME;

EID: 0038339576     PISSN: 10810943     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1078-1439(03)00017-6     Document Type: Conference Paper

References (27)

1. Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591-7.
2. Krongrad A, Lai H, Lai S. Survival after radical prostatectomy. JAMA 1997;278:44-6.
3. Gerber GS, Thisted RA, Scardino PT, et al. Results of radical prostatectomy in men with clinically localized prostate cancer: a multiinstitutional pooled analysis. JAMA 1996;276:615-9.
4. Epstein JI, Pizov G, Walsh PC. Correlation of pathologic findings with progression after radical prostatectomy. Cancer 1993;71:3582-93.
5. Ohori M, Wheeler TM, Scardino PT. The New American Joint Committee on Cancer and International Union Against Cancer TNM classification of prostate cancer: clinicopathologic correlations. Cancer 1994;74:104-14.
6. Zagars GK, Geara FB, Pollack A, et al. The T classification of clinically localized prostate cancer. An appraisal based on disease outcome after radiation therapy. Cancer 1994;73:1904-12.
7. Rubin MA, Bassily N, Sanda M, et al. Relationship and significance of greatest percentage of tumor and perineural invasion on needle biopsy in prostatic adenocarcinoma. Am J Surg Pathol 2000;24:183-9.
8. Stamey TA, McNeal JE, Yemoto CM, et al. Biological determinants of cancer progression in men with prostate cancer. JAMA 1999;281:1395-400.
9. Albertsen PC, Fryback DG, Storer BE, et al. Long-term survival among men with conservatively treated prostate cancer. JAMA 1995; 274:626-31.
10. Gleason DF. Classification of prostatic carcinoma. Cancer Chemother Rep 1966;50:125-8.
11. D'Amico AV, Whittington R Schultz, et al. Outcome-based staging for clinically localized adenocarcinoma of the prostate. J Urol 1997; 158:1422-6.
12. Partin AW, Oesterling JE. The clinical usefulness of prostate-specific antigen: update 1994. J Urol 1994;152:1358-68.
13. de la Taille A, Katz A, Bagiella E, et al. Perineural invasion on prostate needle biopsy: an independent predictor of final pathologic stage. Urology 1999;54:1039-43.
14. Pound CR, Partub AW, Epstein JI, et al. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am 1997;24:395-406.
15. Kattan MW, Stapleton AM, Wheeler TM, et al. Evaluation of a nomogram used to predict the pathologic stage of a clinically localized prostate carcinoma. Cancer 1997;79:528-37.
16. Nelson CP, Rubin MA, Strawderman MS, et al. Preoperative parameters for predicting early prostate cancer recurrence after radical prostatectomy. Urology 2002;59:740-5.
17. Oesterling JE, Brendler CB, Epstein JI, et al. Correlation of clinical stage, serum prostatic acid phosphatase, and preoperative Gleason grade with final pathological stage in 275 patients with clinically localized adenocarcinoma of the prostate. J Urol 1987;138:92-8.
18. Partin AW, Kattan MW, Subong EN, et al. Combination of prostatespecific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: a multi-institutional update. JAMA 1997;277:1445-51.
19. Stein A, deKernion JB, Smith RB, et al. Prostate specific antigen levels after radical prostatectomy in patients with organ confined and locally extensive prostate cancer. J Urol 1992;147:942-6.
20. Epstein JI, Carmichael MJ, Pizov G, et al. Influence of capsular penetration on progression following radical prostatectomy: a study of 196 cases with long-term followup. J Urol 1993;150:135-41.
21. Ohori M, Wheeler TM, Kattan MW, et al. Prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol 1995;154:1818-24.
22. Kattan MW, Eastham JA, Stapleton AM, et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998;90:766-71.
23. D'Amico AV, Chang H, Holupka E, et al. Calculated prostate cancer volume: the optimal predictor of the actual prostate cancer volume. Urology 1997;49:385-91.
24. Presti JC, Shinohara K, Bacchetti P, et al. Positive fraction of systematic biopsies predicts risk of relapse after radical prostatectomy. Urology 1998;52:1079-84.
25. Freedland SJ, Csathy GS, Dorey F, et al. Percent prostate needle biopsy tissue with cancer is more predictive of biochemical failure or adverse pathology after radical prostatectomy than prostate specific antigen or Gleason score. J Urol 2002;167:516-20.
26. Varambally S, Dhanasekaran SM, Zhou M, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002;419:624-629.
27. Rao DS, Hyun TS, Mizukami IF, et al. Huntingtin Interacting Protein 1: a tumor marker of prostate cancer progression. J Clin. Investigation 2002;110:351-360.